Present and future challenges in the treatment of haemophilia: the patient's perspective.
作者信息
Arcieri Romano, Molinari Angelo C, Farace Stefania, Mazza Giuseppe, Garnero Alberto, Calizzani Gabriele, Giordano Paola, Oliovecchio Emily, Mantovani Lorenzo, Manzoli Lamberto, Giangrande Paul
机构信息
Italian Federation of Haemophilia Societies (FedEmo), Rome, Italy.
Italian Federation of Haemophilia Societies Medical Council, Rome, Italy Thrombosis and Haemostasis Unit, Giannina Gaslini Children's Hospital, Genoa, Italy.
出版信息
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s82-5. doi: 10.2450/2013.013s.
Abstract
摘要
相似文献
1
Present and future challenges in the treatment of haemophilia: the patient's perspective.血友病治疗中的当前与未来挑战：患者视角
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s82-5. doi: 10.2450/2013.013s.
2
Present and future challanges in the treatment of haemophilia: a clinician's perspective.血友病治疗中的当前及未来挑战：临床医生视角
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s77-81. doi: 10.2450/2013.012s.
3
[Life with haemophilia. The patient's perspective of ageing].[血友病患者的生活。患者对衰老的看法]
Hamostaseologie. 2013;33 Suppl 1:S22-4.
4
Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee.用于甲型和乙型血友病的凝血因子浓缩剂的最新进展。输血实践委员会。
Transfusion. 1993 May;33(5):422-34. doi: 10.1046/j.1537-2995.1993.33593255605.x.
5
Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients.欧洲血友病患者预防性和按需因子替代疗法之间的生活质量差异
Haemophilia. 2002 Jan;8(1):44-50. doi: 10.1046/j.1365-2516.2002.00581.x.
6
From the voices of people with haemophilia A and their caregivers: Challenges with current treatment, their impact on quality of life and desired improvements in future therapies.从甲型血友病患者及其照顾者的声音中：当前治疗面临的挑战、对生活质量的影响以及对未来治疗的期望改进。
Haemophilia. 2019 May;25(3):433-440. doi: 10.1111/hae.13754. Epub 2019 Apr 23.
7
Advances and innovations in haemophilia treatment.血友病治疗的进展与创新。
Nat Rev Drug Discov. 2018 Jul;17(7):493-508. doi: 10.1038/nrd.2018.70. Epub 2018 Jun 8.
8
Prophylactic treatment of patients with haemophilia A or haemophilia B.对甲型血友病或乙型血友病患者进行预防性治疗。
Vox Sang. 2005 Jan;88(1):62-7. doi: 10.1111/j.1423-0410.2005.00588.x.
9
Switching haemophilia products and inhibitor risk: a United States' perspective.血友病产品转换与抑制物风险：美国视角
Eur J Haematol. 2015 Apr;94(4):283. doi: 10.1111/ejh.12441.
10
The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters.罗丁（血友病患者中抑制剂产生决定因素的研究）研究：血友病治疗者视角下的临床难题。
Haemophilia. 2013 May;19(3):351-4. doi: 10.1111/hae.12149. Epub 2013 Apr 12.
引用本文的文献
1
Development and validation of the Child Hemophilia Treatment Experience Measure: A new observer-reported outcome measure.儿童血友病治疗体验量表的开发与验证：一种新的观察者报告结局指标
Haemophilia. 2025 Jan;31(1):48-62. doi: 10.1111/hae.15102. Epub 2024 Oct 10.
2
Understanding treatment burden in hemophilia: development and validation of the Hemophilia Treatment Experience Measure (Hemo-TEM).理解血友病的治疗负担：血友病治疗体验量表（Hemo-TEM）的开发和验证。
J Patient Rep Outcomes. 2023 Feb 23;7(1):17. doi: 10.1186/s41687-023-00550-6.
3
Comparing regional models of congenital bleeding disorders: preliminary steps in the Italian context.比较先天性出血性疾病的区域模型：意大利背景下的初步步骤。
BMC Res Notes. 2017 Jun 26;10(1):229. doi: 10.1186/s13104-017-2552-6.
4
The Italian institutional accreditation model for Haemophilia Centres.意大利血友病中心的机构认证模式。
Blood Transfus. 2014 Apr;12 Suppl 3(Suppl 3):s510-4. doi: 10.2450/2014.0058-14s.
5
Plasma-derived medicinal products: demand and clinical use.血浆衍生药物产品：需求与临床应用。
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s2-5. doi: 10.2450/2013.002s.
本文引用的文献
1
The demand for factor VIII and for factor IX and the toll fractionation product surplus management.对凝血因子 VIII、凝血因子 IX 的需求以及凝血因子浓缩物产品过剩管理。
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s64-76. doi: 10.2450/2013.011s.
2
The evolution of the regulatory framework for the plasma and plasma-derived medicinal products system in Italy.意大利血浆及血浆衍生药品体系监管框架的演变
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s6-12. doi: 10.2450/2013.003s.
3
Plasma and plasma-derived medicinal product self-sufficiency: the Italian case.血浆及血浆衍生药品的自给自足：意大利的情况
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s118-31. doi: 10.2450/2013.018s.
4
Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.基于绩效的风险分担安排——设计、实施和评估的良好实践：ISPOR 基于绩效的风险分担安排良好实践工作组的报告。
Value Health. 2013 Jul-Aug;16(5):703-19. doi: 10.1016/j.jval.2013.04.011. Epub 2013 Jul 19.
5
Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers.加拿大政策制定者对涉及药品制造商机密折扣的药品报销合同的看法。
Health Policy. 2013 Oct;112(3):248-54. doi: 10.1016/j.healthpol.2013.05.022. Epub 2013 Jun 25.
6
Purchasing factor concentrates in the 21st century through competitive tendering.21 世纪通过竞争性招标集中采购要素。
Haemophilia. 2013 Sep;19(5):660-7. doi: 10.1111/hae.12169. Epub 2013 May 28.
7
Models for institutional and professional accreditation of haemophilia centres in Italy.意大利血友病治疗中心的机构和专业认证模式。
Haemophilia. 2013 Jul;19(4):e248-55. doi: 10.1111/hae.12141. Epub 2013 Apr 5.
8
Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART).随机、对照、平行分组试验：在重度 A 型血友病成人中常规预防与按需使用蔗糖配方重组因子 VIII 的治疗（SPINART）。
J Thromb Haemost. 2013 Jun;11(6):1119-27. doi: 10.1111/jth.12202.
9
Factor VIII products and inhibitor development in severe hemophilia A.VIII 因子产品与严重甲型血友病抑制物的产生。
N Engl J Med. 2013 Jan 17;368(3):231-9. doi: 10.1056/NEJMoa1208024.
10
New challenges in hemophilia: long-term outcomes and complications.血友病的新挑战：长期结局和并发症。
Hematology Am Soc Hematol Educ Program. 2012;2012:362-8. doi: 10.1182/asheducation-2012.1.362.
Zotero 插件